Detection of bone metastases in patients with breast cancer.
Various methods have been evaluated for their ability to detect bone metastases in patients with breast cancer. Bone scanning and hydroxyproline measurements are insensitive and showed metastases in few patients with primary breast cancer despite the fact that most will develop bone metastases. We have therefore investigated the value of examining the bone marrow with immunocytochemical staining for breast carcinoma cells. Initial results in 68 patients with no evidence of bone metastases by conventional means indicated (a) that some patients have breast cancer cells in bone marrow despite having no evidence of dissemination using other tests, and (b) that patients with micrometastases relapse sooner than those patients with normal bone marrows.
D001707:Biopsy, Needle; D001856:Bone Marrow Examination; D001859:Bone Neoplasms / Q000175:diagnosis / Q000556:secondary*; D001842:Bone and Bones / Q000000981:diagnostic imaging; D001943:Breast Neoplasms / Q000473:pathology*; D004164:Diphosphonates; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D011877:Radionuclide Imaging; D013667:Technetium; D013669:Technetium Tc 99m Medronate; D013997:Time Factors
D004164:Diphosphonates; D013667:Technetium; D006909:Hydroxyproline; D013669:Technetium Tc 99m Medronate